• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    UPHEALTH ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS

    8/15/22 7:30:00 AM ET
    $UPH
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $UPH alert in real time by email

    Second Quarter Revenue of $43.7 million, a 21% increase on a Sequential Basis

    Gross Margin Expanded to 51%, compared to 43% on a Sequential Basis

    Nearly 50% of Transformation Initiatives Completed To-Date 

    Subsequent to Quarter End, Company Under New Leadership of CEO Samuel J. Meckey 

    Announced $67.5M Convertible Debt Financing, Further Extending Company's Maturity Profile 

    DELRAY BEACH, Fla., Aug. 15, 2022 /PRNewswire/ -- UpHealth, Inc. ("UpHealth" or the "Company") (NYSE:UPH), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced financial results for the second quarter ended June 30, 2022.

    New UpHealth Logo (PRNewsfoto/UpHealth, Inc.)

    UpHealth CEO Sam Meckey said, "I joined UpHealth because the Company's assets are uniquely situated within the healthcare ecosystem, to solve some of the most pressing problems in healthcare today. The opportunities for UpHealth to create value for our clients are significant and I am eager to contribute my experience and knowledge in healthcare, to help drive our future growth."

    "I am pleased to say that with the company's strategies in place and the foundation to support our transformation, we are well positioned for long-term growth. Together, we look forward to further implementing our strategic vision, uncovering additional ways to unlock value, and delivering for all constituents of UpHealth."

    Meckey also said that he is focused on: "driving growth across all verticals; delivering high-quality, predictable revenue streams; conserving cash; and improving operational excellence, all while creating a culture that attracts and retains top talent who focus intensely on client needs and client service."

    Second Quarter 2022 Financial Highlights:

    • Revenue for the second quarter of 2022 was $43.7 million, a 37% increase compared to GAAP revenue for the second quarter of 2021 of $31.9 million and an 11% increase compared to pro forma revenue for the second quarter of 2021 of $39.2 million.  Gross margin expanded to 51%, up from GAAP and pro forma gross margin in the second quarter of 2021 of 36%. 
    • Revenue and gross margin by segment for the second quarter of 2022 were:
      • Integrated Care Management generated $7.8 million of revenue (18% of total revenue) with a gross margin of 88%.
      • Virtual Care Infrastructure generated $16.8 million of revenue (39% of total revenue) with a gross margin of 49%.
      • Services generated $19.0 million of revenue (44% of total revenue) with a gross margin of 38%.
    • Operating loss for the second quarter of 2022 was $(10.0) million, a 72% improvement compared to operating loss in the second quarter of 2021 of $(35.5) million.
    • Adjusted EBITDA for the second quarter of 2022 was $4.0 million, compared to GAAP and pro forma Adjusted EBITDA for the second quarter of 2021 of $2.2 million and $2.4 million, respectively.

    Please refer to the discussion and tables under "Non-GAAP Financial Information."

    Year-to-Date Second Quarter 2022 Financial Highlights:

    • Year-to-date revenue for the second quarter of 2022 was $79.6 million, a 78% increase compared to year-to-date GAAP revenue for the second quarter of 2021 of $44.7 million and a 14% increase compared to year-to-date pro forma revenue for the second quarter of 2021 of $69.8 million.  Year-to-date gross margin for the second quarter of 2022 expanded to 47%, up from year-to-date GAAP and pro forma gross margin for the second quarter of 2021 of 41% and 40%, respectively. 
    • Year-to-date revenue and gross margin by segment for the second quarter of 2022 were:
      • Integrated Care Management generated $10.4 million of revenue (13% of total revenue) with a gross margin of 82%.
      • Virtual Care Infrastructure generated $32.4 million of revenue (41% of total revenue) with a gross margin of 48%.
      • Services generated $36.8 million of revenue (46% of total revenue) with a gross margin of 37%.
    • Year-to-date operating loss for the second quarter of 2022 was $(28.0) million, a 27% improvement compared to year-to-date operating loss for the second quarter of 2021 of $(38.3) million.
    • Year-to-date Adjusted EBITDA for the second quarter of 2022 was $2.6 million, compared to year-to-date GAAP and pro forma Adjusted EBITDA for the second quarter of 2021 of $2.9 million and $5.4 million, respectively.

    Please refer to the discussion and tables under "Non-GAAP Financial Information."

    Significant Second Quarter Business Highlights:

    • 240 of the over 600 specific transformation milestones completed as of quarter end, and an expectation to be at approximately 80% completion by the end of the third quarter.



    • Martti™ currently supports 224,000 encounters per month and over 34,000 video endpoints at over 2,300 healthcare locations in the U.S. During the second quarter, the Company closed 46 new Martti™ contracts, with over 90 implementations in healthcare facilities nationwide.



    • Executed a contract extension and expansion with the L.A. County Department of Mental Health, expanding UpHealth's work for an additional 12 months, contributing $7.9 million to revenues.



    • The Company recorded its largest volume of telehealth use ever in the U.S. with over 10.6 million minutes of consultations in Q2, compared to 9.4 million minutes in Q1 2022. 



    • HelloLyf consultations in India experienced growth of over 4x with patient consultations increasing by 416K, from 115K in Q2 2021 to 531K in Q2 2022.



    • Finalized a contract with a hospital system to provide an education program for their staff on providing health care for minority populations with the goal of driving better outcomes, reducing readmittance rates and reducing legal penalties for the hospital.



    • Announced the hiring of operations veteran, Daniel Mandoli, as Executive Vice President of our Services Business. Operations optimizations are underway across the pharmacy business.



    • Subsequent to quarter end, the independent directors of UpHealth welcomed the termination of litigation that delayed the Annual Meeting of Stockholders. As a result of the termination of the litigation, the Company will hold its Annual Meeting of Stockholders as soon as practicable.

    Convertible Debt Financing

    The Company announced today the sale of $67.5 million in aggregate principal amount of a new series of variable rate convertible senior secured notes due December 15, 2025 (the "2025 Notes") in a private placement transaction, raising approximately $22.5 million in gross cash proceeds after paying for a repurchase of $45.0 million of its 6.25% convertible senior notes due 2026. The 2025 Notes are convertible into shares of UpHealth common stock at a conversion price of $1.75 per share, which represents a 101% premium over the most recent closing price of UpHealth's common stock.

    The 2025 Notes will be senior secured obligations of UpHealth and will accrue interest at a rate equal to the daily secured overnight financing rate ("SOFR") plus 9.0% per annum, with a minimum rate of 10.5% per annum, payable quarterly in arrears. The 2025 Notes will mature on December 15, 2025, unless earlier repurchased, redeemed or converted. Holders will have the right to convert their 2025 Notes at any time. UpHealth will settle conversions solely in shares of its common stock, except for payments of cash in lieu of fractional shares.

    "We are pleased to announce this milestone transaction. Importantly, the proceeds of this offering will be used to repay the outstanding Seller Notes that mature on September 1, 2022, as well as provide us with the liquidity to execute against our growth plans," commented Martin Beck, CFO of UpHealth. "This transaction provides us with more than three years until any significant borrowings reach maturity, while maintaining the Company's total leverage."

    The 2025 Notes were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and, along with the shares of common stock underlying the 2025 Notes, have not been registered under the Securities Act or applicable state securities laws. Accordingly, the 2025 Notes and the underlying shares of common stock may not be offered, sold, pledged or otherwise transferred except to a qualified institutional buyer (within the meaning Rule 144A under the Securities Act) pursuant to an effective Securities Act registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.

    Oppenheimer & Co Inc. served as exclusive placement agent for the 2025 Notes.

    This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

    Balance Sheet and Cash Flow

    At June 30, 2022, UpHealth reported $41.1 million of cash, cash equivalents and restricted cash. On April 9, 2022, the Company repaid its forward share purchase agreement according to the terms of the contract.

    Conference Call

    UpHealth management will host a live question-and-answer session with investors and analysts beginning at 8:30 a.m. Eastern Time today, August 15, 2022. The call can be accessed live over the telephone by dialing (877) 344-8082, passcode 150118, from the U.S. or International callers can dial (213) 992-4618, passcode 150118. There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at https://investors.uphealthinc.com/events-and-presentations/default.aspx or directly here. The webcast will be archived for approximately 30 days.

    About UpHealth, Inc.                                                                                                                          

    UpHealth is a global digital health company that delivers digital-first technology, infrastructure and services to dramatically improve how healthcare is delivered and managed. The UpHealth platform creates digitally enabled "care communities" that improve access and achieve better patient outcomes at lower cost, through digital health solutions and interoperability tools that serve patients wherever they are, in their native language. UpHealth's clients include global governments, health plans, healthcare providers and community-based organizations. For more information, please visit https://uphealthinc.com and follow us at @UpHealthInc on Twitter and UpHealth Inc on LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Such forward-looking statements include, but are not limited to, the financial statements of UpHealth, its product offerings and developments and reception of its product by customers, statements regarding payments pursuant to the terms of UpHealth's debt obligations and the conversion or maturity of such debt and UpHealth's expectations, hopes, beliefs, intentions, plans, prospects or strategies regarding the future revenue and the business plans of UpHealth's management team. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of UpHealth in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on UpHealth as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting UpHealth will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the ability of UpHealth to service or otherwise pay its debt obligations, the mix of services utilized by UpHealth's customers and such customers' needs for these services, market acceptance of new service offerings, the ability of UpHealth to expand what it does for existing customers as well as to add new customers, that UpHealth will have sufficient capital to operate as anticipated, and the impact that the novel coronavirus and the illness, COVID-19, that it causes, as well as government responses to deal with the spread of this illness and the reopening of economies that have been closed as part of these responses, may have on UpHealth's operations, the demand for UpHealth's products, global supply chains and economic activity in general. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

    Investor Relations:

    Shannon Devine (MZ North America)

    Managing Director

    203-741-8811

    [email protected]

    Media Inquiries:

    Kelsie Aziz (Ketchum)

    Vice President, Financial Communications

    972-408-7103

    [email protected]   

     

    UPHEALTH, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In thousands, except per share amounts, unaudited)





    June 30, 2022



    December 31, 2021

    ASSETS

    Current Assets:







    Cash and cash equivalents

    $                      40,629



    $                      58,192

    Restricted cash

    508



    18,609

    Accounts receivable, net

    28,658



    22,761

    Inventories

    2,966



    2,928

    Due from related parties

    31



    40

    Prepaid expenses and other current assets

    3,785



    4,217

    Total current assets

    76,577



    106,747

    Property and equipment, net

    46,126



    56,072

    Intangible assets, net

    110,563



    115,313

    Goodwill

    284,177



    284,268

    Other assets

    2,768



    6,907

    Total assets

    $                    520,211



    $                    569,307

    LIABILITIES AND STOCKHOLDERS' EQUITY

    Current Liabilities:







    Accounts payable

    $                      18,160



    $                      13,604

    Accrued expenses

    40,065



    36,084

    Deferred revenue

    6,452



    2,649

    Due to related party

    458



    47

    Income taxes payable

    2,731



    739

    Related-party long-term debt, current

    466



    657

    Long-term debt, current

    18,827



    22,093

    Forward share purchase liability

    —



    18,051

    Other current liabilities

    3,069



    2,780

    Total current liabilities

    90,228



    96,704

    Related-party long-term debt, noncurrent

    336



    331

    Long-term debt, noncurrent

    105,243



    98,417

    Deferred tax liabilities

    19,181



    28,281

    Warrant liabilities, noncurrent

    61



    252

    Derivative liability, noncurrent

    1,307



    7,977

    Other long-term liabilities

    2,971



    3,502

    Total liabilities

    219,327



    235,464









    Stockholders' Equity:







    Common stock

    15



    14

    Additional paid-in capital

    683,697



    665,461

    Treasury stock, at cost

    (17,000)



    —

    Accumulated deficit

    (373,092)



    (343,209)

    Accumulated other comprehensive loss

    (7,659)



    (3,802)

    Total UpHealth, Inc., stockholders' equity

    285,961



    318,464

    Noncontrolling interests

    14,923



    15,379

    Total stockholders' equity

    300,884



    333,843

    Total liabilities and stockholders' equity

    $                    520,211



    $                    569,307

     

    UPHEALTH, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (In thousands, except per share amounts, unaudited)





    Three Months Ended June 30,



    Six Months Ended June 30,



    2022



    2021



    2022



    2021

    Revenue:















    Services

    $               28,096



    $               15,448



    $               53,782



    $               23,586

    Licenses and subscriptions

    6,812



    9,145



    8,593



    12,803

    Products

    8,760



    7,289



    17,265



    8,309

    Total revenue

    43,668



    31,882



    79,640



    44,698

    Cost of goods and services:















    Services

    14,762



    9,590



    29,207



    14,063

    License and subscriptions

    217



    6,173



    450



    6,670

    Products

    6,296



    4,727



    12,286



    5,643

    Total cost of goods and services

    21,275



    20,490



    41,943



    26,376

    Gross margin

    22,393



    11,392



    37,697



    18,322

    Operating expenses:















    Sales and marketing

    3,486



    1,695



    6,212



    2,580

    Research and development

    1,782



    2,273



    3,369



    3,843

    General and administrative

    14,632



    7,306



    28,291



    11,029

    Depreciation and amortization

    4,700



    2,966



    9,936



    3,870

    Stock-based compensation

    1,088



    —



    2,462



    —

    Lease abandonment expenses

    —



    —



    75



    —

    Goodwill and intangible asset impairment

    —



    —



    6,174



    —

    Acquisition, integration, and transformation costs

    6,749



    32,653



    9,133



    35,339

    Total operating expenses

    32,437



    46,893



    65,652



    56,661

    Loss from operations

    (10,044)



    (35,501)



    (27,955)



    (38,339)

    Other income (expense):















    Interest expense

    (6,603)



    (4,904)



    (13,598)



    (5,615)

    Gain on consolidation of equity method investment

    —



    —



    —



    640

    Gain on fair value of derivative liability

    1,841



    —



    6,670



    —

    Gain on fair value of warrant liabilities

    95



    1,075



    190



    1,075

    Gain on extinguishment of debt

    —



    151



    —



    151

    Other income (expense), net, including interest income

    14



    (256)



    (2)



    (219)

    Total other expense

    (4,653)



    (3,934)



    (6,740)



    (3,968)

    Loss before income tax benefit

    (14,697)



    (39,435)



    (34,695)



    (42,307)

    Income tax benefit

    2,232



    6,646



    4,525



    7,052

    Net loss before loss from equity method investment

    (12,465)



    (32,789)



    (30,170)



    (35,255)

    Loss from equity method investment

    —



    —



    —



    (561)

    Net loss

    (12,465)



    (32,789)



    (30,170)



    (35,816)

    Less: net loss attributable to noncontrolling interests

    (27)



    (6)



    (287)



    (84)

    Net loss attributable to UpHealth, Inc.

    $              (12,438)



    $              (32,783)



    $              (29,883)



    $              (35,732)

    Net loss per share attributable to UpHealth, Inc.:















    Basic

    $                  (0.09)



    $                  (0.35)



    $                  (0.21)



    $                  (0.43)

    Diluted

    $                  (0.09)



    $                  (0.35)



    $                  (0.21)



    $                  (0.43)

    Weighted average shares outstanding:















    Basic

    144,624



    94,170



    144,581



    83,585

    Diluted

    144,624



    94,170



    144,581



    83,585

     

    UPHEALTH, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In thousands, unaudited)





    Six Months Ended June 30,



    2022



    2021

    Operating activities:







    Net loss

    $                   (30,170)



    $                   (35,816)

    Adjustments to reconcile net loss to net cash used in operating activities:







    Depreciation and amortization

    12,725



    4,353

    Amortization of debt issuance costs and discount on convertible debt

    6,969



    1,913

    Stock-based compensation

    2,462



    —

    Provision for bad debt expense

    (37)



    —

    Impairment of property, plant and equipment, intangible assets and goodwill

    5,459



    —

    Gain on extinguishment of debt

    —



    (151)

    Loss from equity method investment

    —



    561

    Gain on consolidation of equity method investment

    —



    (640)

    Gain on fair value of warrant liabilities

    (190)



    (1,075)

    Gain on fair value of convertible derivative

    (6,670)



    —

    Loss on disposal of property and equipment

    —



    78

    Deferred income taxes

    (4,596)



    (7,262)

    Other

    —



    (271)

    Changes in operating assets and liabilities, net of effects of acquisitions:







    Accounts receivable

    (6,151)



    (21,000)

    Inventories

    (55)



    (80)

    Prepaid expenses and other current assets

    540



    5

    Accounts payable and accrued expenses

    7,913



    15,573

    Income taxes payable

    264



    200

    Deferred revenue

    3,838



    5,877

    Proceeds from Provider Relief Funds

    —



    506

    Due to related parties

    170



    28

    Other current liabilities

    (312)



    (27)

    Net cash used in operating activities

    (7,841)



    (37,228)

    Investing activities:







    Purchases of property and equipment

    (3,783)



    (669)

    Due to related parties

    —



    265

    Net cash acquired in acquisition of businesses

    —



    4,263

    Net cash (used in) provided by investing activities

    (3,783)



    3,859

    Financing activities:







    Proceeds from merger and recapitalization transaction

    —



    83,435

    Proceeds from convertible debt

    —



    164,500

    Repayments of debt

    (3,234)



    (17,333)

    Payments of debt issuance costs

    —



    (8,100)

    Repayment of forward share purchase

    (18,521)



    —

    Payments of seller notes

    —



    (88,056)

    Payments of capital lease obligations

    (1,619)



    (275)

    Payments for taxes related to net settlement of equity awards

    (67)



    —

    Distribution to noncontrolling interest

    (139)



    (100)

    Payments of amount due to member

    —



    (4,270)

    Net cash (used in) provided by financing activities

    (23,580)



    129,801

    Effect of exchange rate changes on cash, cash equivalents, and restricted cash

    (460)



    (99)

    Net (decrease) increase in cash, cash equivalents, and restricted cash

    (35,664)



    96,333

    Cash, cash equivalents, and restricted cash, beginning of period

    76,801



    2,369

    Cash, cash equivalents, and restricted cash, end of period

    $                    41,137



    $                    98,702

    UPHEALTH, INC.

    NON-GAAP FINANCIAL INFORMATION

    Non-GAAP Financial Information

    This press release includes financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). To supplement UpHealth's condensed consolidated financial statements presented in accordance with GAAP, UpHealth presents investors with non-GAAP financial measures, including pro forma revenue, pro forma gross margin and adjusted EBITDA.

    • Pro forma revenue consists of GAAP revenue and revenue from UpHealth's subsidiaries prior to their acquisition.



    • Pro forma gross margin consists of GAAP gross margin and gross margin from UpHealth's subsidiaries prior to their acquisition.



    • Adjusted EBITDA consists of net income (loss) attributable to UpHealth, Inc., excluding depreciation and amortization; stock-based compensation; lease abandonment expenses; goodwill/intangible asset impairment; acquisition, integration, and transformation costs; other income (expense); income tax benefit (expense); income (loss) from equity method investment; net income (loss) attributable to noncontrolling interests; and other non-recurring charges to GAAP net income (loss) attributable to UpHealth, Inc. Other non-recurring charges to GAAP net income (loss) attributable to UpHealth, Inc. may include transaction expenses in connection with capital raising transactions (whether debt, equity or equity-linked) and acquisitions, whether or not consummated, purchase price adjustments, the cumulative effect of a change in accounting principles, or other expenses determined to be non-recurring.

    UpHealth believes that the presentation of these non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to UpHealth's financial condition and results of operations. Management believes that the items described above provide an additional measure of UpHealth's operating results and facilitates comparisons of UpHealth's core operating performance against prior periods and business model objectives. This information is provided to investors in order to facilitate additional analyses of past, present, and future operating performance and as a supplemental means to evaluate UpHealth's ongoing operations. UpHealth believes that these non-GAAP financial measures are useful to investors in their assessment of UpHealth's operating performance.

    Pro forma revenue, pro forma gross margin and adjusted EBITDA are not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. You should not consider these measures in isolation or as a substitute for analysis of UpHealth's results as reported under GAAP. UpHealth compensates for these limitations by prominently disclosing GAAP financial measures and providing investors with reconciliations from UpHealth's GAAP operating results to the non-GAAP financial measures for the relevant periods.

    The accompanying tables provide more details on the GAAP financial measures that are most directly comparable to the non-GAAP financial measures described above and the related reconciliations between these financial measures.

    UPHEALTH, INC.

    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)

    (In thousands)





    Three Months Ended June 30, 2022



    GAAP

    Revenue

    $                                               43,668





    Gross margin

    51 %





    Net loss attributable to UpHealth, Inc.

    $                                             (12,438)

    Net loss attributable to noncontrolling interests

    (27)

    Net loss

    (12,465)

    Other expense

    4,653

    Income tax benefit

    (2,232)

    Loss from equity method investment

    —

    Loss from operations

    (10,044)

    Depreciation and amortization

    6,161

    Stock-based compensation

    1,088

    Acquisition, integration and transformation costs, and non-recurring expenses (2)

    6,749

    Adjusted EBITDA

    $                                                 3,954

     

    (1) See Non-GAAP Financial Information section for definitions of our non-GAAP financial measures.

    (2) Amounts reflect acquisition, integration and transformation costs from the condensed consolidated statements of operations, as well as other operating expenses considered to be non-recurring during the period.

     



    Three Months Ended June 30, 2021



    GAAP



    Adjustments (2)



    Pro Forma (3)

    Revenue

    $                       31,882



    $               7,290



    $                 39,172













    Gross margin

    36 %



    36 %



    36 %













    Net loss attributable to UpHealth, Inc.

    $                     (32,783)



    $             (3,394)



    $               (36,177)

    Net loss attributable to noncontrolling interests

    (6)



    6



    —

    Net loss

    (32,789)



    (3,388)



    (36,177)

    Other expense

    3,934



    (1,180)



    2,754

    Income tax benefit

    (6,646)



    —



    (6,646)

    Loss from equity method investment

    —



    —



    —

    Loss from operations

    (35,501)



    (4,568)



    (40,069)

    Depreciation and amortization

    3,570



    892



    4,462

    Acquisition, integration and transformation costs, and non-recurring expenses (4)

    34,086



    3,895



    37,981

    Adjusted EBITDA

    $                         2,155



    $                  219



    $                   2,374













     

    (1) See Non-GAAP Financial Information section for definitions of our non-GAAP financial measures.

    (2) Amounts reflect operating activity of UpHealth and subsidiaries during the period prior to each subsidiary's acquisition date, if acquired during the period.

    (3) Amounts reflect operating activity of UpHealth and subsidiaries during the period, as if acquired at the beginning of the period.

    (4) Amounts reflect acquisition, integration and transformation costs from the condensed consolidated statements of operations, as well as other operating expenses considered to be non-recurring during the period.

     

    UPHEALTH, INC.

    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)

    (In thousands)





    Six Months Ended June 30, 2022



    GAAP

    Revenue

    $                                        79,640





    Gross margin

    47 %





    Net loss attributable to UpHealth, Inc.

    $                                       (29,883)

    Net loss attributable to noncontrolling interests

    (287)

    Net loss

    (30,170)

    Other expense

    6,740

    Income tax benefit

    (4,525)

    Loss from equity method investment

    —

    Loss from operations

    (27,955)

    Depreciation and amortization

    12,760

    Stock-based compensation

    2,462

    Acquisition, integration and transformation costs, lease abandonment expenses, goodwill and intangible asset impairment, and non-recurring expenses (2)

    15,382

    Adjusted EBITDA

    $                                          2,649

     

    (1) See Non-GAAP Financial Information section for definitions of our non-GAAP financial measures.

    (2) Amounts reflect acquisition, integration and transformation costs, lease abandonment expenses, and goodwill and intangible asset impairment from the condensed consolidated statements of operations, as well as other operating expenses considered to be non-recurring during the period.

     



    Six Months Ended June 30, 2021



    GAAP



    Adjustments (2)



    Pro Forma (3)

    Revenue

    $                       44,698



    $             25,082



    $                 69,780













    Gross margin

    41 %



    37 %



    40 %













    Net loss attributable to UpHealth, Inc.

    $                     (35,732)



    $             (4,317)



    $               (40,049)

    Net loss attributable to noncontrolling interests

    (84)



    28



    (56)

    Net loss

    (35,816)



    (4,289)



    (40,105)

    Other expense

    3,968



    (1,171)



    2,797

    Income tax benefit

    (7,052)



    (99)



    (7,151)

    Loss from equity method investment

    561



    —



    561

    Loss from operations

    (38,339)



    (5,559)



    (43,898)

    Depreciation and amortization

    4,492



    2,729



    7,221

    Acquisition, integration and transformation costs, and non-recurring expenses (4)

    36,772



    5,302



    42,074

    Adjusted EBITDA

    $                         2,925



    $               2,472



    $                   5,397













     

    (1) See Non-GAAP Financial Information section for definitions of our non-GAAP financial measures.

    (2) Amounts reflect operating activity of UpHealth and subsidiaries during the period prior to each subsidiary's acquisition date, if acquired during the period.

    (3) Amounts reflect operating activity of UpHealth and subsidiaries during the period, as if acquired at the beginning of the period.

    (4) Amounts reflect acquisition, integration and transformation costs from the condensed consolidated statements of operations, as well as other operating expenses considered to be non-recurring during the period.

     

    UPHEALTH, INC.

    SEGMENT INFORMATION AND RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)

    (In thousands, unaudited)





    Three Months Ended June 30, 2022



    GAAP

    Revenue:



    Integrated care management (4)

    $                                                        7,823

    Virtual care infrastructure (5)

    16,815

    Services (6)

    19,030

    Total

    $                                                      43,668







    Three Months Ended June 30, 2022



    GAAP

    Gross Margin:



    Integrated care management (4)

    $                                                        6,894

    Virtual care infrastructure (5)

    8,179

    Services (6)

    7,320

    Total

    $                                                      22,393







    Three Months Ended June 30, 2022



    GAAP

    Gross Margin %:



    Integrated care management (4)

    88 %

    Virtual care infrastructure (5)

    49 %

    Services (6)

    38 %

    Total

    51 %





     



    Three Months Ended June 30, 2021



    GAAP



    Adjustments (2)



    Pro Forma (3)

    Revenue:











    Integrated care management (4)

    $                     11,280



    $                            —



    $                     11,280

    Virtual care infrastructure (5)

    6,964



    5,394



    12,358

    Services (6)

    13,638



    1,896



    15,534

    Total

    $                     31,882



    $                       7,290



    $                     39,172















    Three Months Ended June 30, 2021



    GAAP



    Adjustments (2)



    Pro Forma (3)

    Gross Margin:











    Integrated care management (4)

    $                       4,504



    $                            —



    $                       4,504

    Virtual care infrastructure (5)

    2,634



    1,903



    4,537

    Services (6)

    4,254



    750



    5,004

    Total

    $                     11,392



    $                       2,653



    $                     14,045















    Three Months Ended June 30, 2021



    GAAP



    Adjustments (2)



    Pro Forma (3)

    Gross Margin %:











    Integrated care management (4)

    40 %



    n/a



    40 %

    Virtual care infrastructure (5)

    38 %



    35 %



    37 %

    Services (6)

    31 %



    40 %



    32 %

    Total

    36 %



    36 %



    36 %













     

    UPHEALTH, INC.

    SEGMENT INFORMATION AND RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)

    (In thousands, unaudited)





    Six Months Ended June 30, 2022



    GAAP



    Revenue:





    Integrated care management (4)

    $                                                      10,435



    Virtual care infrastructure (5)

    32,445



    Services (6)

    36,760



    Total

    $                                                      79,640











    Six Months Ended June 30, 2022



    GAAP



    Gross Margin:





    Integrated care management (4)

    $                                                        8,531



    Virtual care infrastructure (5)

    15,588



    Services (6)

    13,578



    Total

    $                                                      37,697











    Six Months Ended June 30, 2022



    GAAP



    Gross Margin %:





    Integrated care management (4)

    82 %



    Virtual care infrastructure (5)

    48 %



    Services (6)

    37 %



    Total

    47 %









     



    Six Months Ended June 30, 2021



    GAAP



    Adjustments (2)



    Pro Forma (3)

    Revenue:











    Integrated care management (4)

    $                     17,569



    $                            —



    $                     17,569

    Virtual care infrastructure (5)

    7,554



    15,603



    23,157

    Services (6)

    19,575



    9,479



    29,054

    Total

    $                     44,698



    $                     25,082



    $                     69,780















    Six Months Ended June 30, 2021



    GAAP



    Adjustments (2)



    Pro Forma (3)

    Gross Margin:











    Integrated care management (4)

    $                       9,723



    $                            —



    $                       9,723

    Virtual care infrastructure (5)

    2,933



    6,097



    9,030

    Services (6)

    5,666



    3,157



    8,823

    Total

    $                     18,322



    $                       9,254



    $                     27,576















    Six Months Ended June 30, 2021



    GAAP



    Adjustments (2)



    Pro Forma (3)

    Gross Margin %:











    Integrated care management (4)

    55 %



    n/a



    55 %

    Virtual care infrastructure (5)

    39 %



    39 %



    39 %

    Services (6)

    29 %



    33 %



    30 %

    Total

    41 %



    37 %



    40 %













    UPHEALTH, INC.

    SEGMENT INFORMATION AND RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)

    (In thousands, unaudited)





    (1)

    See Non-GAAP Financial Information section for definitions of our non-GAAP financial measures.





    (2)

    Amounts reflect operating activity of UpHealth and subsidiaries during the period prior to each subsidiary's' acquisition date, if acquired during the period.





    (3)

    Amounts reflect operating activity of UpHealth and subsidiaries during the period, as if acquired at the beginning of the period.



    Segment Information

    Our business is organized into three operating business segments:

    Integrated Care Management—through our Thrasys subsidiary;

    Virtual Care Infrastructure—through our Glocal and Cloudbreak subsidiaries; and

    Services—through our Innovations, BHS and TTC subsidiaries.

    The reportable segments are consistent with how management views our services and products and the financial information reviewed by the chief operating decision makers. We manage our businesses as components of an enterprise for which separate information is available and is evaluated regularly by the chief operating decision makers in deciding how to allocate resources and assess performance.





    (4)

    In the Integrated Care Management segment, we provide our customers with an advanced, comprehensive, and extensible technology platform, marketed under the umbrella "SyntraNetTM" to manage health, quality of care, and costs, especially for individuals with complex medical, behavioral health, and social needs.





    (5)

    In the Virtual Care Infrastructure segment, we provide technology and process-based healthcare platforms providing our customers comprehensive primary care, specialty consultations, and translation services, through telemedicine, Digital Dispensaries, and technology-based hospital centers.





    (6)

    In the Services segment, we provide custom compounded medications for the unique needs of every patient and prescriber. We are a full-service pharmacy filling prescriptions from our inventory of compounded medications, as well as drugs purchased from manufacturers. Additionally, we provide inpatient and outpatient substance abuse and mental health treatment services for individuals with drug and alcohol addiction and other behavioral health issues. We offer a complete continuum of care from detoxification services, residential care, partial hospitalization programs, and intensive outpatient and outpatient programs.





     

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/uphealth-announces-second-quarter-2022-financial-results-301605493.html

    SOURCE UpHealth, Inc.

    Get the next $UPH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $UPH

    DatePrice TargetRatingAnalyst
    3/31/2022$6.00 → $1.00Buy → Hold
    Lake Street
    10/25/2021$6.00Buy
    Lake Street
    7/22/2021$12.00Outperform
    Oppenheimer
    7/13/2021$13.00Outperform
    Northland Capital
    More analyst ratings

    $UPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Beck Martin S A

      4 - UpHealth, Inc. (0001770141) (Issuer)

      2/15/24 4:29:53 PM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 4 filed by Locke Nathan

      4 - UpHealth, Inc. (0001770141) (Issuer)

      2/2/24 6:24:51 PM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Greene James S was granted 100,000 shares (SEC Form 4)

      4 - UpHealth, Inc. (0001770141) (Issuer)

      2/2/24 6:23:53 PM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology

    $UPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UpHealth downgraded by Lake Street with a new price target

      Lake Street downgraded UpHealth from Buy to Hold and set a new price target of $1.00 from $6.00 previously

      3/31/22 8:59:33 AM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Lake Street initiated coverage on UpHealth with a new price target

      Lake Street initiated coverage of UpHealth with a rating of Buy and set a new price target of $6.00

      10/25/21 9:33:22 AM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Oppenheimer initiated coverage on UpHealth with a new price target

      Oppenheimer initiated coverage of UpHealth with a rating of Outperform and set a new price target of $12.00

      7/22/21 7:07:38 AM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology

    $UPH
    SEC Filings

    See more
    • SEC Form DEFA14A filed by UpHealth Inc.

      DEFA14A - UpHealth, Inc. (0001770141) (Filer)

      2/15/24 4:48:59 PM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology
    • UpHealth Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - UpHealth, Inc. (0001770141) (Filer)

      2/15/24 4:44:09 PM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form DEFM14A filed by UpHealth Inc.

      DEFM14A - UpHealth, Inc. (0001770141) (Filer)

      1/24/24 6:06:58 AM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology

    $UPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UpHealth Announces CEO Transition and Organizational Changes

      Jay Jennings Appointed Acting Chief Executive Officer of UpHealth; Replacing Martin Beck Announces the Promotion of Lisa Fluxman to President of TTC Healthcare Reaffirms Jeremy Livianu as Chief Legal Officer and Secretary of UpHealth DELRAY BEACH, Fla., July 15, 2024 /PRNewswire/ -- UpHealth, Inc. ("UpHealth," the "Company") (NYSE:UPH), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced the July 11, 2024 appointment by the Board of Directors of the Company of Jay Jennings, currently the Company's Chief Financial Officer, to serve as the Company's Acting Chief Executive Officer, replac

      7/15/24 4:15:00 PM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology
    • The International Court of Arbitration awarded UpHealth Holdings more than $110 Million in Damages in Breach of Contract Lawsuit Involving the 2020 Purchase by UpHealth of Glocal Healthcare Systems

      DELRAY BEACH, Fla., March 20, 2024 (GLOBE NEWSWIRE) -- UpHealth, Inc. ("UpHealth") (OTC:UPHL), a global digital health company delivering a full continuum of behavioral health solutions through the utilization of evidence-based treatments and services, today provided an update on the arbitration brought by UpHealth Holdings, Inc., a wholly-owned direct subsidiary of UpHealth ("Holdings"), against Glocal Healthcare Systems ("Glocal") and several of Glocal's officers and shareholders (together with Glocal, the "Respondents"). On March 18, 2024, the International Court of Arbitration of the International Chamber of Commerce (the "ICA") transmitted the Final Award to the parties. In the Final

      3/20/24 5:00:04 PM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology
    • UpHealth Completes Sale of Cloudbreak Health at $180 Million Full Cash Deal

      DELRAY BEACH, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- UpHealth, Inc. ("we," "our," "UpHealth," or the "Company") (NYSE:UPHL) today announced that it completed its previously announced sale of Cloudbreak Health, LLC ("Cloudbreak"), best known for its Martti™ translation offering, to a newly formed entity controlled by GTCR LLC for $180 million in gross cash proceeds on March 15, 2024. The $180 million in gross proceeds will be used to pay all closing expenses including any potential liability for taxes on the sale and paying down the Company's debt, including all of the Company's $115 million 2026 Notes and a substantial portion of its $57.2 million 2025 Notes. "This transaction is one m

      3/18/24 8:30:10 AM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology

    $UPH
    Leadership Updates

    Live Leadership Updates

    See more
    • UpHealth Announces CEO Transition and Organizational Changes

      Jay Jennings Appointed Acting Chief Executive Officer of UpHealth; Replacing Martin Beck Announces the Promotion of Lisa Fluxman to President of TTC Healthcare Reaffirms Jeremy Livianu as Chief Legal Officer and Secretary of UpHealth DELRAY BEACH, Fla., July 15, 2024 /PRNewswire/ -- UpHealth, Inc. ("UpHealth," the "Company") (NYSE:UPH), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced the July 11, 2024 appointment by the Board of Directors of the Company of Jay Jennings, currently the Company's Chief Financial Officer, to serve as the Company's Acting Chief Executive Officer, replac

      7/15/24 4:15:00 PM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology
    • UpHealth Announces CEO Transition and Organizational Changes

      Martin Beck Appointed CEO, Replacing Samuel Meckey Announces the Elimination of 20 Corporate Roles DELRAY BEACH, Fla., Oct. 11, 2023 (GLOBE NEWSWIRE) -- UpHealth, Inc. ("UpHealth," the "Company") (NYSE:UPH), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced the October 5, 2023 appointment by the Board of Directors of the Company of Martin Beck to serve as the Company's next Chief Executive Officer, replacing Samuel Meckey, effective October 6, 2023, and Mr. Beck being named as a member of the Board of Directors effective October 9, 2023. Mr. Beck has been UpHealth's Chie

      10/11/23 8:30:00 AM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology
    • UpHealth Announces Results of First Annual Stockholder Meeting

      Proposed New Independent Board Members Elected Stockholders Approved Reverse Split of the Company's Shares Stockholders Approve New Independent Auditor DELRAY BEACH, Fla., Dec. 05, 2022 (GLOBE NEWSWIRE) -- UpHealth, Inc. (NYSE:UPH) announces the results of its first annual stockholder meeting, held December 5, 2022, virtually. All resolutions submitted for stockholder approval were adopted, including the following: Election of three Class I directors to hold office until the 2025 annual meeting and until their respective successors are elected and qualified.Approval of reverse stock split.Ratification of the appointment of BPM LLP as independent registered public accountin

      12/5/22 4:11:00 PM ET
      $COLB
      $UMPQ
      $UPH
      Savings Institutions
      Finance
      Commercial Banks
      Retail: Computer Software & Peripheral Equipment

    $UPH
    Financials

    Live finance-specific insights

    See more
    • UpHealth Announces Second Quarter 2023 Financial Results

      Second Quarter Revenues Were $37.8 million and Gross Margin Expanded to 53% Year-to-Date Net Loss Attributable to UpHealth, Inc. Improved 9% to $27.2 million Year-to-Date Adjusted EBITDA Improved by $9.2 million to $11.8 million Closed Strategic Sale of Innovations Group, Inc. for $56.0 million Completed Repurchase of $10.3 Million of Convertible Debt Increasing Full Year 2023 Outlook DELRAY BEACH, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) -- UpHealth, Inc. ("UpHealth" or the "Company") (NYSE:UPH), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced financi

      8/10/23 4:15:05 PM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology
    • UpHealth Announces Timing of Second Quarter 2023 Earnings Release and Conference Call

      DELRAY BEACH, Fla., July 25, 2023 (GLOBE NEWSWIRE) -- UpHealth, Inc. (NYSE:UPH) ("UpHealth" or the "Company"), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced that it will release financial results for its second quarter ended June 30, 2023, after market close on Thursday, August 10, 2023. A conference call to discuss the results will follow at 5:00 p.m. Eastern Time on the same day. Those wishing to participate via the webcast should access the call through UpHealth's Investor Relations website at https://investors.uphealthinc.com. Those wishing to participate via the telep

      7/25/23 8:30:00 AM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology
    • UpHealth Announces First Quarter 2023 Financial Results

      First Quarter Revenues Increased 17% to $42.1 millionFirst Quarter Gross Margin Expanded to 54% First Quarter Net Loss Attributable to UpHealth, Inc. Decreased 54% to $8.1 millionFirst Quarter Adjusted EBITDA Improved by $7.9 million to $6.6 million Announced Strategic Sale of Innovations Group, Inc. for $56.0 million DELRAY BEACH, Fla., May 11, 2023 (GLOBE NEWSWIRE) -- UpHealth, Inc. ("UpHealth" or the "Company") (NYSE:UPH), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced financial results for the first quarter ended March 31, 2023. UpHealth Chief Executive Officer Sam Meckey

      5/11/23 4:08:05 PM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology

    $UPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by UpHealth Inc. (Amendment)

      SC 13D/A - UpHealth, Inc. (0001770141) (Subject)

      11/29/23 4:03:50 PM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form SC 13D/A filed by UpHealth Inc. (Amendment)

      SC 13D/A - UpHealth, Inc. (0001770141) (Subject)

      11/27/23 8:34:32 PM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form SC 13D filed by UpHealth Inc.

      SC 13D - UpHealth, Inc. (0001770141) (Subject)

      11/27/23 8:20:19 PM ET
      $UPH
      Retail: Computer Software & Peripheral Equipment
      Technology